Joyce A. O'Shaughnessy, MD

Articles

Dr O’Shaughnessy on Real-World Data for Tucatinib-Based Therapy in HER2+ Breast Cancer

April 11th 2023

Joyce A. O’Shaughnessy, MD, discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer.

Dr. O’Shaughnessy on DESTINY-Breast02 and DESTINY-Breast03 in Metastatic HER2+ Breast Cancer

January 20th 2023

Joyce A. O’Shaughnessy, MD, discusses key data from the phase 3 DESTINY-Breast02 and DESTINY-Breast03 trials in metastatic HER2-positive breast cancer.

Dr. O’Shaughnessy on Pembrolizumab in Triple-Negative Breast Cancer

August 23rd 2022

Joyce A. O’Shaughnessy, MD, discusses the sequencing of pembrolizumab with chemotherapy in patients with early-stage triple-negative breast cancer.

Optimizing Treatment Strategies in Breast Cancer: Q&A

June 8th 2022

Fielding questions from their live audience, Joyce O'Shaughnessy, MD, and Sara Hurvitz, MD, discuss optimal selection of therapy for patients with breast cancer.

Clinical Trials in HER2+ mBC: DESTINY-Breast03 and HER2CLIMB

June 8th 2022

Highlights of the results from the DESTINY-Breast03 and HER2CLIMB trials, evaluating T-DXd and tucatinib, respectively, in HER2+ metastatic breast cancer.

Patient Scenario: HER2+ Metastatic Breast Cancer

June 1st 2022

Joyce O'Shaughnessy, MD, and Sara Hurvitz, MD, consider how they would approach the treatment of a patient with HER2+ metastatic breast cancer.

KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC

June 1st 2022

Expert perspectives on adjuvant and neoadjuvant use of pembrolizumab in the KEYNOTE-522 study in triple-negative breast cancer.

Selecting Novel Adjuvant Therapy For Patients With Breast Cancer

May 25th 2022

Following their discussion on the OlympiA and monarchE trials in breast cancer, experts consider when they would use olaparib or abemaciclib in the adjuvant setting.

Adjuvant Abemaciclib in Early Breast Cancer: The monarchE Trial

May 25th 2022

Shared insight on the monarchE trial, which studied adjuvant abemaciclib in patients with HR+, HER2- high-risk early breast cancer.

Adjuvant Olaparib in BRCA-Mutated Breast Cancer: The OlympiA Trial

May 18th 2022

Highlights from the OlympiA trial, which evaluated the use of olaparib in the adjuvant setting in patients with high-risk BRCA-mutated breast cancer.

Breast Cancer: The Evolving Neoadjuvant and Adjuvant Treatment Landscape

May 18th 2022

Joyce O'Shaughnessy, MD, provides a brief overview of novel neoadjuvant and adjuvant treatment approaches being investigated in the setting of breast cancer.

Impact of Molecular Testing on Treatment Options in Breast Cancer

May 11th 2022

Shared insight on specific treatment options in breast cancer made available when patients are found to have actionable targets via molecular testing.

Molecular Testing Platforms in Breast Cancer

May 11th 2022

Expert perspectives on platforms for molecular testing in breast cancer, as well as the actionable targets that treating physicians should be looking for.

ESMO 2021: Updates in Triple Negative Breast Cancer

November 15th 2021

Drs Joyce O’Shaughnessy, Sara Tolaney, Sara Hurvitz, and Mark Pegram examine recent trial data from ESMO 2021 on triple-negative breast cancer.

Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial

November 8th 2021

Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.

Multidisciplinary Care in ILD Management: Role of a Pulmonologist

October 22nd 2021

Shared insight on the benefit of multidisciplinary care and the pulmonologist’s role in identifying and managing interstitial lung disease.

Role of Bronchoscopy in Identifying and Managing ILD

October 15th 2021

Charles A. Powell, MD, MBA, leads a discussion on bronchoscopy’s role in identifying interstitial lung disease.

Optimizing the Management of ILD: Steroids, Therapy Cessation, and Dose Modification

October 15th 2021

A broad review of strategies to manage interstitial lung disease, including steroid use, therapy cessation/rechallenging, and dose reduction.

Managing ILD: Taking Therapeutic Class Into Account

October 8th 2021

Brief considerations for the impact an agent’s therapeutic class can have on how interstitial lung disease should be approached.

Approaching the Management of Interstitial Lung Disease

October 8th 2021

Experts consider the mainstays in ILD management and factors that may dictate one treatment strategy over another.